Explore the Agenda
7:00 am Check In, Morning Coffee & Light Refreshments
7:55 am Chair’s Opening Remarks
Beyond the Topo1 Dogma: Unveiling Rationale-Driven Novel Payload Development & Properties to Herald ADCs with New Mechanisms & Improved Therapeutic Index
8:00 am Showcasing Non-Cytotoxic Payload Attributes, Selection & Performance to Enhance ADC Therapeutic Index Beyond the Cytotoxic Dogma
- Understanding the importance of antibody epitope, influence of target isoforms and impact on internalization
- Unveiling detailed investigation of unique payloads to develop non-cytotoxic ADCs with improved therapeutic index beyond traditional conjugates
- Undergoing investigation of antigen internalization and tumor cell payload concentration to secure in-depth mechanistic understanding and benefit of antibody-mediated delivery
- Laying out takeaways for non-cytotoxic ADC development and applications to internal ADC development
8:30 am Unlocking the Full Potential of Antibody Conjugates: AJICAP® Technology for Precise DAR Control and Emerging Modality Applications
- AJICAP® Conjugation: Leveraging site-specific technologies in next-generation ADCs to enhance clinically relevant biological properties through precise DAR control such as 1, 2, 4, 8 and higher
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and enables versatile synthesis of ADCs with higher DAR numbers, even with highly hydrophilic payloads
- Application for new modality conjugates: Bispecific antibodies and antibody-oligonucleotide conjugates produced by fully chemical conjugation technology
9:00 am Pan-RASi ADCs: Spotlighting Optimization of RAS-Inhibitor Payloads to Differentiate ADC Mechanism Beyond Topo1
- Telling the rationale and development story of Pan-RASi platform as a novel ADC mechanism to combat Topo1 saturation
- Showcasing the journey through RASi-ADC proof of concept iterative development to prototype ADC
- Highlighting prototype ADC in vitro, ex vivo and PD data to demonstrate initial performance in RAS mutated cancers
9:30 am Leveraging Bioconjugation Strategies to Enhance AOC CMC Processes
- Navigating the nuances of oligonucleotide conjugate process development and understanding how to leverage physiochemical properties and chemistry aspects between different AOCs
- Comparing AOCs with classical ADCs: Explore payload complexity, impurity profiles, and essential analytical methods
- Assessing the evolving regulatory framework, impurity control, stability, immunogenicity and target product profiles
- Spotlighting real-world customer case studies that demonstrate a risk-managed approach to get to the clinic quicker
10:00 am Morning Break & Scientific Poster Showcase
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Leveraging Novel Payload Mechanisms & Combinations to Combat Topo1 & MMAE Patient Resistance
Theme 1: Evaluating ADC & AOC Development to Assess Therapeutic Potential in Autoimmune Indications
Presentation Preview: Exploring Development of E7766-Based STING ADCs: Influence of Payload Linker Attachment Site & Cleavage Kinetics
Sr Principal Scientist, Eisai Co., Ltd.
- Delving into discovery of STING-agonist payload E7766, focusing on payload-linker attachment site
- Investigating linker cleavage rate to enhance in vitro and in vivo antitumor activities
- Showcasing in vitro and in vivo preclinical data of E7766-based STING ADCs
4 sessions
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
1:00 pm Lunch & Networking
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Theme 2: Leveraging ADC Chemistry & Structure Insights to Develop Novel Conjugation Methods & Enhance ADC Design
Presentation Preview: Evaluating Enzymatic Conjugation Strategies to Improve Dual Payload ADC Therapeutic Index at the Discovery Stage
Senior Director, ADC Enabling Technologies, OBI Pharma, Inc.
- Employing innovative conjugation chemistry to deliver two distinct payloads to the antibody Fc region
- Optimizing conjugation process across DAR fine tuning and payload selection to reduce dual to enhance developability while accelerating candidate selection
- Showcasing impact of discovery-stage innovation to deliver ADC properties and differentiation potential to patients
3 sessions
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
3:30 pm Afternoon Break & Networking
Delving Into ADC Performance in Crowded Clinical Indications With Approved ADC Therapies to Understand How Differences in Biconjugate Design & Clinical Strategy Correlates to Patient Impact
4:00 pm Spotlighting the Clinical Performance of Izalontamab Brengitecan Bispecific ADC
- Breaking down design and development of Iza-Bren, a EGFR/HER3 bispecific ADC, including advantages against traditional monospecific ADC therapies
- Evaluating Iza-Bren clinical profile based on recent clinical trials
- Laying out ongoing clinical development of Iza-Bren through bispecific ADC advantages and impactful clinical profile
4:30 pm Laying Out Advances in ADC Development & Manufacturing
- Discussing tools used for the efficient and scalable manufacturing of the mAb intermediate, which serves as a key starting point for ADC conjugation
- Overcoming ADC mAb diversity challenges via AI-driven cell line design
- Explaining operator safety risk-mitigation enabled by agnostic, automated solutions
5:00 pm Highlighting the Clinical Promise from Phase I/IIa Development of TUB-040 in Platinum Resistant Ovarian Cancer
- Explaining TUB-040 ADC design innovation across payload, conjugation and validated NaPi2b target
- Detailing proof-of-concept data and strong ORR from the emerging clinical profile of TUB-040
- Contrasting clinical performance to preclinical data to assess how well TUB-040 innovation has been translated into patient studies
- Highlighting the clinical development strategy and potential therapeutic impact of TUB-040 in PROC with an existing approved ADC therapy
5:30 pm Chair’s Closing Remarks
6:00 pm 13th World ADC Awards
At the end of the main conference days, join the community for an unforgettable gala honoring the best programs, companies and individuals in the ADC field. Across multiple award categories, this is your opportunity to reflect and recognize the long-term contributors, novel and innovative programs, and upcoming pioneers who have gone above and beyond to deliver the continued success and future direction of the field.